u/pavel_kravchenko

What jurisdiction are you asking about? The answer has changed in several.

Where a supplier holds regional stock, ask which lines are actually held there rather than drop-shipped. It changes the lead time and it changes the customs question.

Telogen shedding follows a period of significant weight change rather than a specific compound, and it resolves.

That is the first-month offer price, not the ongoing monthly cost. The tracker records the second one.

Same. The injection was the thing I was most nervous about and the thing that turned out to matter least.

A rejected claim at the pharmacy counter and a denied authorization are different events with different remedies. The first can be an administrative or quantity issue; the second is a determination you can appeal.

Xi'an Health Biochem shows up in threads constantly and has almost nothing on file

Research-use-only material is not approved for human use. That is a plain statement of regulatory fact and it belongs in every beginner thread.

Disagree. That is the pathway in one ICB and it does not generalise even to the next one over.

Agreed that appetite moves before the scale. Knowing that in advance saves a lot of week-three panic.

503A is patient-specific, 503B is outsourcing facility, they are not the same thing

Did the consultation ask about history and medication?

What concentration is on the label, and does it match what you were expecting?

tier 3 waiting lists are measured in years, not months

ask for the mass spectrum, not just the purity number

cormac_roos is right that a pure something-else is still something else.

no question is too basic here, that is the entire point of the board

A private prescription is an independent route: it does not affect NHS list position, and it is not a step in the same pathway.

Disagreeing with this line: that is the arrangement in one nation and the question is about another.

What is the beyond-use date and what is it based on?

A certificate with a purity figure and no method line is not falsifiable. You cannot reproduce it, you cannot check it, and it tells you nothing about how the number was produced.

Cosigning that the papers are more modest than the summaries of them. That is true across this whole site and especially here.

Is there a quantity limit involved rather than a coverage refusal?

Have you seen the special authorization criteria for your province?

private plans and provincial plans are different fights entirely

That is a report count, not a test count.

Agreed — and the corollary is that "no data" and "bad data" have to be written differently. The table separates them for exactly that reason.

ask the pharmacy for the price list, not the headline offer

Careful.

hassan_chowdhury is right about the concentration trap. It breaks arithmetic that has been reliable for months.

private plans and provincial plans are different fights entirely

Where a supplier holds regional stock, ask which lines are actually held there rather than drop-shipped. It changes the lead time and it changes the customs question.

the wider-market names in the table are there because nobody has enough data on them

Yes. Nothing here is approved for human use and that should be the first line of every thread, not the last.

no referral links, ever, and that rule is why the pricing threads work

That is not what patient-specific means. It refers to the prescription, not to a customisation of the formula.

Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.

Did you ask for the batch-specific certificate, or the generic one?

Retitled — the original claimed a composition change the scans cannot distinguish.

This is the whole intervention. Protein and resistance training.

Protein was the whole problem. Appetite dropped and I was eating well under target without noticing for a month.

Same DEXA machine both times?

Agreed — and keeping the letters with dates is what makes any later challenge possible.

ahmed_okafor is right that the two routes are separate. A private prescription does not move you up the list.

Disagree — that is your province’s formulary position and it does not carry to another.

That reads as a recommendation and the source pages deliberately are not. They are a record you use to make your own decision.